Results 91 to 100 of about 20,567 (248)

Comparing the effects of biguanides and dipeptidyl peptidase-4 inhibitors on cardio-cerebrovascular outcomes, nephropathy, retinopathy, neuropathy, and treatment costs in diabetic patients.

open access: yesPLoS ONE
BackgroundWestern guidelines often recommend biguanides as the first-line treatment for diabetes. However, dipeptidyl peptidase-4 (DPP-4) inhibitors, alongside biguanides, are increasingly used as the first-line therapy for type 2 diabetes (T2DM) in ...
Eiji Nakatani   +14 more
doaj   +1 more source

Research Progress of Common Organic Guanidine Antibacterial Agents

open access: yesTo Chemistry Journal, 2020
Aim: The aim of this study is to investigate the antimicrobial properties of organic guanidine because of their strong alkalinity, high stability, low toxicity and good biological activity.
Hua Li   +3 more
doaj  

Atom‐by‐Atom Multimetal CuMoP Deposition on Carbon Electrodes for Sensitive Antidiabetic Metformin Electrooxidation

open access: yesAnalytical Science Advances, Volume 7, Issue 1, June 2026.
An atom‐by‐atom ternary Cu–Mo–P nanocomposite is electrochemically co‐deposited onto screen‐printed carbon electrodes to create a highly active sensing interface for metformin detection. The porous mixed‐valence network enhances electroactive surface area and charge transfer, enabling sensitive and selective electrooxidation with a low detection limit.
Hong Wan   +4 more
wiley   +1 more source

Comparison of decision tree with common machine learning models for prediction of biguanide and sulfonylurea poisoning in the United States: an analysis of the National Poison Data System [PDF]

open access: gold, 2023
Omid Mehrpour   +6 more
openalex   +1 more source

Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway

open access: yesCell Reports Medicine
Summary: The biguanide metformin attenuates mitochondrial oxidation and is proposed as an anti-cancer therapy. However, recent clinical studies suggest increased proliferation and fatty acid β-oxidation (FAO) in a subgroup of patients with breast cancer (
Jun Hyoung Park   +25 more
doaj   +1 more source

Unveiling Candidate Markers for Drug Resistance or Synthetic Lethality in Cervical Cancer: Integrative Analysis of Genetic and Pharmacoprofiling

open access: yesCancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Introduction Systemic cervical cancer management continues to be challenging. Numerous chemotherapies have been approved, but predicting response is difficult due to the lack of biomarkers. Here, we analyze the genetic and protein profiles of 20 cervical cancer cell lines (CCCLs) and explore their correlation with drug response patterns to ...
Suzy Scholl   +10 more
wiley   +1 more source

Lactate metabolism and lactylation in female reproductive diseases: From metabolic rewiring to biomarkers and translational therapeutics

open access: yesClinical and Translational Medicine, Volume 16, Issue 6, June 2026.
1. Lactate‐derived histone lactylation links glycolytic reprogramming to epigenetic regulation in female reproductive diseases. 2. In endometriosis, lactylation may promote inflammatory remodelling, immune dysregulation and ferroptosis resistance. 3. In PCOS, lactylation connects metabolic disturbance to granulosa‐cell dysfunction and hyperandrogenism.
Jiajun Qiao   +5 more
wiley   +1 more source

Beyond Glycolysis: Targeting Non‐Glycolytic Metabolic Pathways in Brain Tumors for Therapeutic Innovation: A Narrative Review

open access: yesHealth Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Metabolic reprogramming is a hallmark of brain tumors, extending beyond the classical Warburg effect. While glycolysis has been extensively studied, gliomas and pediatric high‐grade brain cancers demonstrate remarkable metabolic plasticity.
Iffat Islam Mayesha   +5 more
wiley   +1 more source

Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis.

open access: yesPLoS Biology, 2015
Metformin is a biguanide widely prescribed to treat Type II diabetes that has gained interest as an antineoplastic agent. Recent work suggests that metformin directly antagonizes cancer cell growth through its actions on complex I of the mitochondrial ...
Takla Griss   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy